...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, needs to break out of .28 and .42 for a sustained move higher.
Looks like it. Personalized medicine is the way to go - precision targeted medicine - gene based biomarkers.
Barnhill and Norris are out there educating the folks.
Each one of us need to do our own DD.
Unprecedented --- record volume --- 6 million shares traded and climbing!
It is good that Norris continues to be COO ... looks like his contract has been renewed but no PR about it.
5 million and counting - in just 2 hours
HDVY made it to the Buzz cloud and is #5 on the breakout boards today
... and there goes the 4 million on the volume - and we are hardly a little over an hour on this today
Perhaps a perfect confluence of events ...
* Major indices are up
* Yesterday's chart showed the right ingredients for a move up.
investorshub.advfn.com/boards/read_msg.aspx?message_id=46008328
* The recent conference on personalized medicine.
* New coverage by other agencies
Could this be it ???
And now if the PR comes out from the company ...
Cheers
2.5mm already within the 1st hour - hard to believe that a coverage would cause this much volume!
Nice start for the day .... if we can only get a PR to light the rocket
- and has suddenly started releasing a stream of PR - as if on a campaign blitz!
It was quiet all these weeks/months - and then since Xmas time, boom - 3-4 a month now!
Good for us!
Last time we saw this kind of volume -- was in mid October - when HDVY peaked at .4
I wonder if it is a bunch of doctors - just deciding to accumulate - after hearing Barnhill/Norris at the conference.
Chart is looking good ... now we need to sustain this momentum.
Interesting news snippet ... from Yahoo msg board - Bold & Underlining are by me.
=========================
From Quests conference call
Kevin Ellich – RBC Capital Markets
Thinking about your relationships with some of the small diagnostic testing companies like Vermillion and the launch of OVA1 actually could you give us some color and detail behind what’s going with OVA1 launch when its expected? What other diagnostic testing categories you’re interested in or looking at?
Surya Mohapatra
Let me first start with the diagnostic category, we are focusing on pre-diagnostic areas infectious disease, cardiovascular disease and cancer diagnostics. One of the major reasons for acquisition of AmeriPath that we want to be the destination for cancer patients when it comes to cancer diagnostics so that’s going on as well as far as integration is concerned. Now we are working with other companies whether it is Vermillion or whether it is other companies where we are bringing in new gene-based testing. Some of these companies were for years and we are very excited that Vermillion is come up with OVA1 and we’re going to introduce it this quarter.
As far as going forward you heard the same thing about Epigenomics as far as ColoVantage, colorectal cancer you will see us more and more doing gene-based and esoteric testing whether it’s for personalized medicine or whether it is just medicine to improve specificity and sensitivity almost all aspects of cancer
Tom Gallucci – Lazard Capital Markets
You mentioned pathology along with gene-based and esoteric as important areas. We’ve been seeing and hearing for a long time about a shift toward more in house operations. Can you give us an update on what your thoughts are on the pathology landscape generally?
Surya Mohapatra
As you know, over the last five or six years, every year very disciplined way we are growing, now we have 800 MDs in the company. We have a number of specialists whether it is pathology or it is humanopathology. Once you build this what I call the brain power, our doctors are seeing more patients a day then some of the hospitals. One of the questions I ask the companies, who is looking at your slides? This is our really great, great strength and we want to really leverage.
Another way of leveraging is really to combining clinical pathology and anatomic pathology and molecular diagnostics and you’re seeing some of these results and obviously people talk about personalized medicine, that’s what we’re doing. Once we combine with the digital pathology we think this is going to really give us a really unique advantage to really move forward.
We see some in-sourcing in the hospitals and people are trying to do what I call the individual analysis that where you see some decrease in the anatomic pathology in the tissue. I don’t think it’s a long term trend because people are going to really come to us for more then just the tissue.
Bob Hagemann
You’ll see out on our website that the anatomic pathology business for the year was essentially flat year over year and I think a lot of that slowdown had to do with the in-sourcing. The anatomic pathology is just a piece of the broader market for cancer diagnostics and given the molecular test that we offer which are often getting ordered now in conjunction with tissue and other AP work, we feel as though we’re very, very well positioned for the long term, particularly with the 800 pathologists that we’ve got on board to offer consultations.
I hear ya TSBob ... it does get frustrating.
This PPS looks better in the 20s than when it was in the single digits!
Keep the faith! I know you will ... for a little longer.
Cheers
I was hoping for some action end of January - as a result of the conference.
Question is - will Barnhill release some news PR - to sustain a follow through.
...or it could be just new folks who got excited after Barnhill & Norris spoke in a conference... and want to be a part of this company!
Let's see how this turns out.
Good volume 1.67 million - and it is just past noon.
2010 will be the year of Electronic Medical Records...
Stay long - if you can stomach the roller coaster ride.
I will add at .15 and below IF it goes there.
Hope this dip is for a short time.
Wow - a lot of posts today questioning the price!
I do hope you are all invested in other equities (both bigger stocks and pennies) - and not have to rely on just this company! There are so many many plays - both small & large cap.
I am long this company and believe in its ability to deliver.
If it drops to .15 I will add to the pile.
Do your DD (and all of us have done here prior to buying this company) and stick to it.
Stay Long and Prosper.
Cheers,
That's great news - this has not hit all the news agencies yet. More folks will become aware once it hits the other news outlets.
Ihub has not yet shown this news.
Great research! Thank you for sharing.
True - it is out of its trading range of .20 - .25
Question is, for how long or is it just a momentary plunge.
For me, the reasons I purchased this stock remain the same.
Yes it is hard to stomach it.
I would look at it this way - the MMs have shorted while in the trading range and are now covering their shorts after taking out stops.
If you can afford it, accumulate on dips.
Can drive one "nuts" trying to analyze ... I just let go.
As we know, because it is in a trading range - until it breaks out of it - nothing much will happen - can't do a thing about it.
Yes - yesterday's volume traded in just 3 hours today.
0.02 right around the corner --- wow - the speed of this ascent is amazing. From .01 to .02 in such a short time!
Good observation vcpace!
Imagine what will happen if it gets "more attention" ... let it run - we sit back and watch!
It will likely pullback, base and push higher.
Looks like 2010 is turning out to be the Electronic Medical Records inflection point - when things converge to make it happen.
Best to all.
.01 printed ... yess!
.009 printed !
Good posts "tryn2makamil"!
Good to see more validation by other companies that are using HDVY's SVM technology to create new and innovative tests.
Wonder what financial impact it will have for HDVY.
This statement in that PR "Financial terms of the deal were not disclosed", dated 2006 does not give us any clues.
What would be ideal if HDVY can get it as a cash flow streaming through, for each test sold by DGX on behalf of Epigenomics.
I would think Dr. Barnhill would have negotiation such a deal - to have streaming % cash flow on a test basis rather than a one time payment to HDVY.
Hi TechStockBob, I am not placing any limit sell orders. I would rather wait and see how the ticker responds to the Quest expected news - and also watch the strength of the response.
Besides, that is not the only event that is expected, so I plan to hold onto this beyond that.
Best to you.
Terrific post Bobafett - thank you for sharing.
Yes, holding patiently ... and let the zeroes move from one side of the decimal to the other!
Closed at high of the day... nice finish
Good post Ry5577 - once this breaks this 50s trading ceiling, it should go higher.
More folks will be getting the "message" that PHR (personal health record) is something that one should have with them all the time - much more important than the credit score.
2010 should be a good year for MDFI.
Have been holding this for a few months but not had posted in this board.
Best to all. Cheers,
Anyone know what is going on .... popping up today!
Is this because of next week's JPM biotech as indicated by Heyo?
Another event during the week of Jan 25th!
Quest Diagnostic to release 4th Qtr and Full year Results on Jan 25th...
Quest Diagnostics To Release Fourth Quarter and Full Year 2009 Financial Results
Last update: 1/8/2010 9:27:00 AM
MADISON, N.J., Jan 08, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth-quarter and full year 2009 results and provide financial guidance for 2010 on Monday, January 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day.
The public may access the conference call through a live audio webcast available on Quest Diagnostics' Investor Relations internet site at .
The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at or by phone at 866-428-3803 for domestic callers, or 203-369-0904 for international callers. No access code will be required.